Acetylcholine-releasing agents as cognition enhancers. Structure-activity relationships of pyridinyl pendant groups on selected core structures.

doi:10.1016/S0960-894X(00)80543-0

Bioorganic & Medicinal Chemistry Letters

Volume 2, Issue 8, August 1992, Pages 851-854

https://doi.org/10.1016/S0960-894X(00)80543-0 Get rights and content

Abstract

A number of analogs of the cognition enhancing agent DuP 996 were prepared by varying the core structure and pendant groups in an independent fashion. The SAR of 2-, 3-, and 4-pyridinylmethyl groups as pendant groups on selected cores was examined.

Abstract

References (17)

R.T. Bartus
Pharmacol. Biochem. Behav.
(1978)
K.L. Davies et al.
Psychopharmacol. Bull.
(1983)
C.G. Gottfries
Psychopharamcology
(1985)
F.V. DeFeudis
Drugs Today
(1988)
F.M. Hershenson et al.
J. Med. Chem.
(1986)
W.H. Moos et al.
Med. Res. Rev.
(1988)
R.T. Bartus et al.
Z. Bohdanechy et al.
Int. J. Neuropharmacol.
(1967)

There are more references available in the full text version of this article.

Cited by (13)

An anthrone-based Kv7.2/7.3 channel blocker with improved properties for the investigation of psychiatric and neurodegenerative disorders
2019, Bioorganic and Medicinal Chemistry Letters
A set of novel Kv7.2/7.3 (KCNQ2/3) channel blockers was synthesized to address several liabilities of the known compounds XE991 (metabolic instability and CYP inhibition) and the clinical compound DMP 543 (acid instability, insolubility, and lipophilicity). Using the anthrone scaffold of the prior channel blockers, alternative heteroarylmethyl substituents were installed via enolate alkylation reactions. Incorporation of a pyridazine and a fluorinated pyridine gave an analog (compound 18, JDP-107) with a promising combination of potency (IC₅₀ = 0.16 μM in a Kv7.2 thallium flux assay), efficacy in a Kv7.2/7.3 patch clamp assay, and drug-like properties.
Pharmacology of the Neurotransmitter Release Enhancer Linopirdine (DuP 996), and Insights into Its Mechanism of Action
1996, Advances in Pharmacology
Drugs that enhance the release of neurotransmitters, or that otherwise affect neurotransmission via a presynaptic action have potential use in a wide range of neurological diseases, including perhaps Alzheimer's disease, Parkinsonism, and depression. The discovery of linopirdine [DuP 996]; 3,3-bis(4-pyridinylmethyl)-1-phenylindolin-2-one; AVIVA^TM offered a new approach to the improvement of cholinergic function, and the drug has subsequently been used in clinical trials in Alzheimer's patients. Linopirdine was found to increase the release of ACh and other neurotransmitters in response to a depolarizing stimulus. By facilitating neurotransmission only during neuronal firing, it might be expected that the functioning of impaired cholinergic pathways in the CNS could be improved. There is no reason to suppose that the cholinergic approach to the treatment of Alzheimer's disease would reverse the gross histological manifestations of the disease: the neurofibrillary tangles and neuritic (senile) plaques. Continued studies on the etiology of Alzheimer's are clearly of the utmost importance in determining new strategies for drug treatment, and possibly also for prevention. The nature of the disease causes it to severely impact the families of patients, as well as the patients themselves, and it is currently the fourth leading cause of death in the United States. Clinical management of Alzheimer's disease is handicapped by the heterogeneity of the illness, and by the difficulty of detecting it in the earlier stages. This chapter reviews the pharmacological actions of linopirdine with a particular emphasis on understanding the mechanism by which these effects are achieved. It is hoped that a better understanding of linopirdine's action can lead to new improved compounds, and perhaps can suggest new target sites for the treatment of Alzheimer's disease and other neurological disorders.
Acetylcholine release enhancers related to linopirdine: A structure-activity relationship study. II
1996, European Journal of Medicinal Chemistry
Several series of α,α-disubstituted polycyclic compounds were found to enhance the stimulus-induced release of neurotransmitters, especially acetylcholine, in brain slices. This work resulted in the identification of linopirdine [3,3-bis (4-pyridinylmethyl)-1, 3-dihydro-1-phenyl-2H-indol-2-one] 1a which was tested clinically for the treatment of Alzheimer's disease. The structure-activity relationship (SAR) results suggest that the potency of the series was dependent on the nature of the pendent groups (R), the distance geometry produced by the pendant groups, and the hydrogen-bonding property of the core group.
Metabolic and Pharmaceutical Aspects of Fluorinated Compounds
2020, Journal of Medicinal Chemistry
Efficient pyridinylmethyl functionalization: Synthesis of 10,10-bis[(2-fluoro-4-pyridinyl)methyl]-9(10H)-anthracenone (DMP 543), an acetylcholine release enhancing agent
2000, Journal of Organic Chemistry
Alzheimer's
2000, Chemical Innovation

View all citing articles on Scopus

¹: Present address: Programme Management CNS Drugs, Scientific Development Group, Organon International B.V., P.O. Box 20, 5340 BH Oss, The Netherlands.

View full text

Acetylcholine-releasing agents as cognition enhancers. Structure-activity relationships of pyridinyl pendant groups on selected core structures.

Abstract

Abstract

Pharmacol. Biochem. Behav.

Psychopharmacol. Bull.

Psychopharamcology

Drugs Today

J. Med. Chem.

Med. Res. Rev.

Int. J. Neuropharmacol.